114 related articles for article (PubMed ID: 10116423)
1. ABMT (autologous bone marrow transplantation): a microcosm of the U.S. health care system.
McGivney WT
Physician Exec; 1992; 18(1):45-7. PubMed ID: 10116423
[TBL] [Abstract][Full Text] [Related]
2. ABMT and breast cancer: what have we learned?
Brown E
Physician Exec; 1999; 25(4):86-8. PubMed ID: 10557495
[TBL] [Abstract][Full Text] [Related]
3. Cost-effective use of autologous bone marrow transplantation: few answers, many questions, and suggestions for future assessments.
Hillner BE; Smith TJ; Desch CE
Pharmacoeconomics; 1994 Aug; 6(2):114-26. PubMed ID: 10147437
[TBL] [Abstract][Full Text] [Related]
4. Federal courts still split on autologous bone marrow transplants.
Margolis RE
Healthspan; 1992 Dec; 9(11):20-2. PubMed ID: 10123554
[No Abstract] [Full Text] [Related]
5. Two views on HDCT-ABMT breast cancer treatment controversy. Too experimental for insurers--or just too expensive?
Carter RD; Coleman DM; Bennett JE
Healthspan; 1992 Jan; 9(1):10-5. PubMed ID: 10117134
[No Abstract] [Full Text] [Related]
6. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer.
Peters WP; Rogers MC
N Engl J Med; 1994 Feb; 330(7):473-7. PubMed ID: 8289855
[TBL] [Abstract][Full Text] [Related]
7. Evaluating promising new treatments for life-threatening disease: implications of the HDC/ABMT experience for treating breast cancer.
Edwards S
Find Brief; 2005 Jan; 8(1):1-3. PubMed ID: 15672527
[No Abstract] [Full Text] [Related]
8. Perspectives. Indefinite results in ABMT (autologous bone marrow transplantation) trials add to challenges for practice standards, quality assurance in cancer care.
Cunningham R
Med Health; 1999 Apr; 53(16):suppl 1-4. PubMed ID: 10387749
[No Abstract] [Full Text] [Related]
9. Last chance therapies and managed care. Pluralism, fair procedures, and legitimacy.
Daniels N; Sabin JE
Hastings Cent Rep; 1998; 28(2):27-41. PubMed ID: 9589291
[TBL] [Abstract][Full Text] [Related]
10. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support.
Winer EP; Lindley C; Hardee M; Sawyer WT; Brunatti C; Borstelmann NA; Peters W
Psychooncology; 1999; 8(2):167-76. PubMed ID: 10335560
[TBL] [Abstract][Full Text] [Related]
11. The role of bone marrow transplantation in the management of advanced local disease.
Safah H; Weiner RS
Surg Oncol Clin N Am; 1995 Oct; 4(4):735-49. PubMed ID: 8535908
[TBL] [Abstract][Full Text] [Related]
12. Health insurance: coverage of autologous bone marrow transplantation for breast cancer.
Jaggar SF
Oncology (Williston Park); 1996 Sep; 10(9):1329-32, 1337-8, 1340 passim. PubMed ID: 8882925
[No Abstract] [Full Text] [Related]
13. Tide turning against autologous bone marrow transplants in federal appellate courts.
Margolis RE
Healthspan; 1993 Jun; 10(6):21-2. PubMed ID: 10127304
[No Abstract] [Full Text] [Related]
14. The mandate for investigational cancer therapies.
Brown E
Physician Exec; 1995 Sep; 21(9):46-7. PubMed ID: 10151483
[TBL] [Abstract][Full Text] [Related]
15. Experimental treatment: can you do the right thing without going broke?
Holoweiko M
Bus Health; 1995 May; 13(5):38-40, 45-6, 48. PubMed ID: 10164496
[No Abstract] [Full Text] [Related]
16. Public health service. Reassessment autologous bone marrow transplantation.
Handelsman H
Health Technol Assess Rep; 1988; (3):1-18. PubMed ID: 3078429
[No Abstract] [Full Text] [Related]
17. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
[TBL] [Abstract][Full Text] [Related]
18. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies.
Vicent MG; Madero L; Chamorro L; Madero R; Diaz MA
Haematologica; 2001 Oct; 86(10):1087-94. PubMed ID: 11602415
[TBL] [Abstract][Full Text] [Related]
19. Health insurance coverage for emerging medical technologies: a new approach.
Puzio D
Tort Trial Insur Pract Law J; 2003; 38(4):1019-47. PubMed ID: 14503539
[No Abstract] [Full Text] [Related]
20. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
